Incyte (MEX:INCY) Moat Score: 7/10 (As of Jul. 05, 2026)


MEX:INCY Incyte Corp MEX:INCY
84 GF Score
Price MXN1,676.03
GF Value MXN1,427.46
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Incyte Moat Score?

Incyte MEX:INCY 84 Moat Score is 7 as of Jul. 05, 2026. GuruFocus rates MEX:INCY with a GF Score™ of 84/100 and a GF Value™ of MXN1,427.46 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,399 Biotechnology companies, Incyte ranks better than 99.57% on this metric.

Incyte has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Incyte has Wide Moat: Incyte Corp has a wide moat due to its strong portfolio of patented drugs, significant R&D capabilities, and established market presence. Its intellectual property and regulatory exclusivity provide durable competitive advantages in the biotech sector.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Incyte might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Incyte  (MEX:INCY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Incyte Moat Score Related Terms

MEX:INCY vs INSM, BNTX, ROIV: Moat Score Comparison

For the Biotechnology subindustry, Incyte's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Incyte Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Moat Score distribution charts can be found below:

* The bar in red indicates where Incyte's Moat Score falls into.


MEX:INCY
84GF Score
Incyte Corp MEX:INCY
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
Incyte (MEX:INCY) has a Moat Score of 7 as of Jul. 05, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Incyte ranks #6 out of 1399 companies in the Biotechnology industry, placing it in the top 0.40000000000001%.
Is Incyte's Moat Score too high?
Incyte's current Moat Score is 7. The Biotechnology industry median Moat Score is 2.00. Incyte's value of 7 is 250% above this industry median. Based on the distribution chart, Incyte ranks #6 out of 1399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Incyte has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's Moat Score compare to INSM and BNTX?
According to the Biotechnology industry distribution chart, Incyte ranks #6 out of 1399 companies for Moat Score. This places Incyte in the top 0% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Incyte's value of 7 is 250% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Incyte's current Moat Score of 7 is 250% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Incyte's current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN1,427.46, compared to a current price of MXN1,676.03 — trading 17.4% above its estimated fair value. The current Moat Score is 7 and 250% above the Biotechnology industry median of 2.00. Incyte's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Incyte (MEX:INCY), the current Moat Score is 7 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Incyte (MEX:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of MXN1,676.03 is trading 17.4% above its estimated GF Value™ of MXN1,427.46. GuruFocus considers Incyte to be Modestly Overvalued.

Key valuation signals for MEX:INCY:

  • Moat Score: 7
  • GF Value™: MXN1,427.46 vs. price of MXN1,676.03 (17.4% above fair value)
  • GF Score™: 84/100 with 4 warning signs
  • Industry Position: 250% above the Biotechnology median (#6 of 1399)

No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
84GF Score

Get the complete analysis for MEX:INCY

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,676.03
Price
MXN1,427.46
GF Value